Long-term treatment with rotigotine in drug-naïve PSP patients
- 103 Downloads
Progressive supranuclear palsy (PSP) is a severe neurodegenerative disease still lacking of alleviating treatments for either cognitive or motor disturbances. Aimed at widening the spectrum of therapeutic options, here, we describe efficacy and safety of a long-term treatment with Rotigotine, a non-ergolinic dopamine agonist, in PSP. Seven PSP drug-naïve patients, presenting with Richardson’s syndrome, received up to 6 mg/24 h transdermal patch for 42 weeks as unique therapy. Adverse effects were recorded; efficacy was measured by comparing baseline and final treatment scores of Montreal Cognitive Assessment (MoCA), Unified Parkinson Disease Rating Scale part3, and PSP rating scale (PSP-RS). At the end of our observation, no significant adverse events occurred; the cognitive item of PSP-RS was improved and MoCA score was similar at baseline. Contrariwise, motor disturbances worsened according to disease progression. Our observation thus suggests that long-term treatment with low doses of rotigotine is well tolerated and may support cognitive functions of PSP patients.
KeywordsPSP Progressive supranuclear palsy Dementia Parkinsonism Rotigotine
No funding has been received for this study.
Compliance with ethical standards
Conflict of interest
The authors declare no conflicts of interest.
The study was conducted according with institutional ethical standards and the Helsinki declaration.
All participants signed an informed consent.
- 22.Fiorenzato E, Weis L, Falup-Pecurariu C et al (2016) Montreal cognitive assessment (MoCA) and mini-mental state examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy. J Neural Transm 123:1435–1442. https://doi.org/10.1007/s00702-016-1589-3 CrossRefGoogle Scholar
- 25.Brenneis C, Seppi K, Schocke M et al (2004) Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 75:246–249Google Scholar